BAM
TGTX icon

Belpointe Asset Management’s TG Therapeutics TGTX Stock Holding History

Belpointe Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Buy
+50,719
New +$2.08M 0.09% 209
2023
Q2 		– Sell
-6,750
Closed -$102K – 3104
2023
Q1 		$102K Buy
6,750
+4,654
+222% +$70.7K 0.01% 1299
2022
Q4 		$24.8K Buy
+2,096
New +$15.2K ﹤0.01% 2031
2018
Q4 		– Sell
-43,435
Closed -$243K – 629
2018
Q3 		$243K Buy
+43,435
New +$496K 0.04% 407

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Belpointe Asset Management's TGTX Position: Q2 2026 in Review

Belpointe Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 50,719 shares worth $2.79M. The stake represents 0.09% of the portfolio and ranks #209 among its holdings. This is a return to the name: Belpointe Asset Management previously reported a position in TGTX as recently as Q1 2023.

Belpointe Asset Management first reported a position in TGTX in Q3 2018 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Belpointe Asset Management held 50,719 shares of TG Therapeutics worth $2.79M as of Q2 2026.
  • TG Therapeutics was a new Belpointe Asset Management position in Q2 2026.
  • TG Therapeutics made up 0.09% of Belpointe Asset Management's portfolio in Q2 2026, its #209 holding.
  • Belpointe Asset Management first reported a position in TG Therapeutics in Q3 2018 and has held it in 4 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.